Invivyd IVVD 深 滬
等待開盤 11-04 09:30:00 美东时间
0.5815
0.000
-0.09%
華盛通- 最 高0.62
- 今 開0.601
- 成交量 931.95万股
- 最 低 0.5575
- 昨 收 0.582
- 總市值 1.71亿
- 52周最高 3.0699
- 市盈率 靜 --
- 換手率 3.16%
- 52周最低 0.5277
- 委 比 -89.04%
- 總股本 2.95亿
- 歷史最高 78.82
- 量 比 2.32
- 振 幅 10.74%
- 歷史最低 0.3546
- 每 手 1
- 風險率 0.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. (Nasdaq: IVVD) announced on November 1, 2026, that it granted stock options to seven newly hired non-executive employees, totaling 175,000 shares, as inducements for their employment. The options were granted under Nasdaq Listing Rule 5635(c)(4) and the Invivyd, Inc. 2026 Inducement Plan. Each option has an exercise price of $0.5817, the closing price on October 30, 2026. The options vest over four years, with 25% vesting after the ...
11-03 12:01
Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for bo...
10-21 19:12
Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome
The Phase 2 FLINTLOCK clinical trial includes the following study features: Randomized, double-blind, placebo-controlled, proof-of-concept study Tests Invivyd’s monoclonal antibody VYD2311, an investigational monoclonal antibody that has been demonstrated to be pharmaceutically active against all SA...
10-14 19:05
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
Invivyd, Inc. and the SPEAR Study Group have initiated the FLINTLOCK Phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome. The trial is a randomized, double-blind, placebo-controlled study assessing VYD2311 administered in three doses over 90 days. VYD2311 has shown high antiviral potency...
10-14 11:01
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. (Nasdaq: IVVD) announced on October 1, 2026, that it granted stock options to six newly hired non-executive employees, totaling 157,500 shares, as inducements for their employment. The options, granted under the 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), have an exercise price of $0.8165 per share, vesting over four years with monthly installments after the first anniversary. The options have a 10-year term. Invivyd is...
10-05 11:01
Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccine VYD2311 combined with an mRNA-based COVID-...
09-29 19:05
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
Invivyd's VYD2311 monoclonal antibody demonstrated superior safety and tolerability compared to an mRNA-based COVID-19 vaccine in the LIBERTY Phase 3 trial, with no interference with vaccine-induced neutralizing titers. The study showed that VYD2311 alone or combined with the vaccine significantly reduced adverse events and enhanced immune responses. Invivyd plans to submit a Biologics License Application (BLA) under the FDA's Accelerated Approva...
09-29 11:01
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target
BTIG analyst Thomas Shrader reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
09-14 20:24
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. granted 255,000 stock options to six new non-executive employees on September 1, 2026, under its 2026 Inducement Plan. The options, exercisable at $0.8799 per share, vest over four years and have a 10-year term. Invivyd, a biopharmaceutical company focused on viral infectious diseases, aims to develop best-in-class antibodies.
09-03 11:01
